NCT07062211

Brief Summary

This research will employ cross-sectional analytical to determine diagnostic accuracy of Flourodeoxyglucose-18 Positron Emission Computed Tomography in the evaluation of Recurrent Papillary Thyroid Carcinoma with patient's raised Thyroglobulin level in Lahore.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
39

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Mar 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 17, 2025

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

June 24, 2025

Completed
20 days until next milestone

First Posted

Study publicly available on registry

July 14, 2025

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2025

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2026

Completed
Last Updated

July 14, 2025

Status Verified

July 1, 2025

Enrollment Period

6 months

First QC Date

June 24, 2025

Last Update Submit

July 2, 2025

Conditions

Papillary Thyroid Carcinoma

Outcome Measures

Primary Outcomes (1)

  • Nominal self admsinitered questioner

    Scoring in a nominal scale involves assigning a unique numerical or symbolic code to each category. For instance, in a gender survey, you might code male as "1" and female as "2." However, these codes are purely for identification and do not imply any order or magnitude

    12 Months

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This research will employ cross-sectional analytical to determine diagnostic accuracy of Flourodeoxyglucose-18 Positron Emission Computed Tomography in the evaluation of Recurrent Papillary Thyroid Carcinoma with patient's raised Thyroglobulin level

You may qualify if:

  • Patients include both male and female from 18years to 80years
  • Patients presented with raised thyroglobulin
  • Patients with suspected diagnosis of recurrent papillary thyroid carcinoma

You may not qualify if:

  • Patients exclude both male and female below 18years and above 80years
  • All the patients presented with carcinoma other than papillary carcinoma.
  • All the patients with normal thyroglobulin level.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

INMOL hospital

Lahore, Punjab Province, Pakistan

Location

MeSH Terms

Conditions

Thyroid Cancer, Papillary

Condition Hierarchy (Ancestors)

Adenocarcinoma, PapillaryAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsThyroid NeoplasmsEndocrine Gland NeoplasmsNeoplasms by SiteHead and Neck NeoplasmsEndocrine System DiseasesThyroid Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

June 24, 2025

First Posted

July 14, 2025

Study Start

March 17, 2025

Primary Completion

September 1, 2025

Study Completion

March 1, 2026

Last Updated

July 14, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations

PA(1)